Nasdaq cprx.
Their CPRX share price targets range from $24.00 to $27.00. On average, they expect the company's share price to reach $24.75 in the next twelve months. This …
The $210.13 million and $245.56 million estimates for the current and next fiscal years indicate changes of +49.2% and +16.9%, respectively. Last Reported Results and Surprise History. Catalyst ...Aug 2, 2023 · Fintel reports that on August 11, 2023, Cantor Fitzgerald maintained coverage of Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight recommendation. Analyst Price Forecast Suggests 52.12% Upside 09/26/2022. 5.23%. 95,058,928. 4,970,704. 7,496,361. 1. Data brought to you by Benzinga APIs. Looking for the most shorted stocks? Short interest for Catalyst Pharmaceuticals gives investors a ... CPRX technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Catalyst Pharmaceuticals, Inc. is based on the …
Oct 28, 2021 · Most readers would already be aware that Catalyst Pharmaceuticals' (NASDAQ:CPRX) stock increased significantly by 9.4% over the past month. Since the market usually pay for a company’s long-term ...
CPRX technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Catalyst Pharmaceuticals, Inc. is based on the …
Catalyst Pharmaceuticals' CEO is Pat McEnany, appointed in Jan 2002, has a tenure of 21.83 years. total yearly compensation is $6.92M, comprised of 10% salary and 90% bonuses, including company stock and options. directly owns 3.86% of the company’s shares, worth $57.92M. The average tenure of the management team and the board of …Shares of NASDAQ:CPRX opened at $14.82 on Monday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 28.50 and a beta of 1.11. …Find the latest on option chains for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Selling, general and administrative expenses totaled $14.7 million, up from $13.2 million reported in the year-ago quarter. As of Dec 31, 2022, CPRX had cash, cash equivalents and investments ...CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive ...
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) was founded in 2002 and generated its first profits in 2019. The 10-year results are summarized below. The 10-year results are summarized below. CPRX ...
CORAL GABLES, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “the Company”) (Nasdaq: CPRX) today reported financial results for the second quarter of 2023 and provided a corporate update.
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) · Latest CPRX News | Press Releases · Today's Trading · Growth & Valuation · Competitors · Financials · Profile · Forecasts.That number of contracts represents approximately 900,900 underlying shares, working out to a sizeable 56.5% of CPRX's average daily trading volume over the past month, of 1.6 million shares.Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, focused on developing and commercializing therapies for patients with rare debilitating ...Catalyst Pharmaceuticals CPRX has had a good run this year. The stock has surged 43% in the year-to-date period against the industry’s decline of 18.7%.. Image Source: Zacks Investment Research ...CORAL GABLES, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has successfully completed …
Catalyst Pharmaceuticals CPRX has reached a settlement with Jacobus Pharmaceutical Company, Inc. and PANTHERx Rare LLC, with regard to the ongoing patent infringement litigation over its sole ...Find the latest SEC Filings data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Dec 4, 2023 · CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive ... Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, focused on developing and commercializing therapies for patients with rare debilitating ...To wit, the Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) share price has soared 514% over five years. This just goes to show the value creation that some businesses can achieve.Stock analysis for Catalyst Pharmaceuticals Inc (CPRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Catalyst Pharmaceuticals Inc share price live 13.860, this page displays NASDAQ CPRX stock exchange data. View the CPRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Catalyst Pharmaceuticals Inc real time stock price chart ...
Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why. (Zacks) -5.61%. Feb-07-23 08:03AM. Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance.The price-to-earnings ratio for Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) is above average at 12.30x, while the 36-month beta value is 1.08.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”While the historical EPS growth rate for Catalyst is 42.6%, investors should actually focus on the projected growth. The company's EPS is expected to grow 56% this year, crushing the industry ...Catalyst Pharmaceutical (CPRX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") CPRX today announced the appointment of Michael W. Kalb as its Executive Vice ...Most readers would already be aware that Catalyst Pharmaceuticals' (NASDAQ:CPRX) stock increased significantly by 9.4% over the past month. Since the market usually pay for a company’s long-term ...Find the latest press releases from Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Catalyst also expects a cash balance of $191 million as of 2021-end, without any funded debt. For 2022, the company expects total revenues for 2022 in the range of $195-$205 million, suggesting a ...For the last reported quarter, Catalyst came out with earnings of $0.20 per share versus the Zacks Consensus Estimate of $0.19 per share, representing a surprise of 5.26%. For the previous quarter ...
Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Cetera Investment Advisers grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 7.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).The fund owned 15,223 shares of the biopharmaceutical company’s stock after acquiring an …
Catalyst Pharmaceuticals CPRX is expected to report its fourth-quarter 2022 results sometime in the middle of March. Catalyst Pharmaceuticals’ earnings surprise history has been mixed so far ...Nov 10, 2023 · Earnings vs Savings Rate: CPRX's forecast earnings growth (25.8% per year) is above the savings rate (2.2%). Earnings vs Market: CPRX's earnings (25.8% per year) are forecast to grow faster than the US market (14.7% per year). High Growth Earnings: CPRX's earnings are expected to grow significantly over the next 3 years. Catalyst Pharmaceutical (CPRX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...Find the latest dividend history for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com. A look at the shareholders of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership.While the historical EPS growth rate for Catalyst is 42.6%, investors should actually focus on the projected growth. The company's EPS is expected to grow 56% this year, crushing the industry ...Shares of NASDAQ:CPRX opened at $14.82 on Monday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 28.50 and a beta of 1.11. The stock’s 50-day simple moving ...Starbucks’ (NASDAQ:SBUX) 100% Return Could Be Coming At A Cost Dec 2, 2020 Tesla Inc., (NASDAQ:TSLA) is Getting Stronger, and it may be Time to Reevaluate Feb 11, 2022 Calculating The Fair Value ...Cetera Investment Advisers grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 7.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,223 shares of the biopharmaceutical company’s stock after acquiring an additional 1,096 shares during the quarter. Cetera […]CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive ...
10 hours ago · CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive ... NasdaqCM:CPRX Insider Trading Volume August 29th 2021. I will like Catalyst Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of growing companies with ...Turning to the calls side of the option chain, the call contract at the $15.00 strike price has a current bid of $1.70. If an investor was to purchase shares of CPRX stock at the current price ...Instagram:https://instagram. vanguard windsor fundtarget walmartmoney market fund bestwho owns survey monkey While the historical EPS growth rate for Catalyst is 42.6%, investors should actually focus on the projected growth. The company's EPS is expected to grow 92.3% this year, crushing the industry ...Back to CPRX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. mlp etfetf tip Did Catalyst Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Catalyst Pharmaceuticals (NASDAQ: ... sila stock While the historical EPS growth rate for Catalyst is 42.6%, investors should actually focus on the projected growth. The company's EPS is expected to grow 92.3% this year, crushing the industry ...Catalyst Pharmaceuticals, Inc. CPRX announced that the FDA has accepted its supplemental new drug application ("sNDA") seeking a label expansion for its flagship product, Firdapse (amifampridine).Apr 13, 2021 · A look at the shareholders of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership.